BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
2019 · Nature Communications · 180 citations
https://doi.org/10.1038/s41467-019-11048-5
T
Timo Reisländer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
16
Papers
708
Citations
7
h-index
6
i10-index
Timo Reisländer is an academic researcher from Servier (Germany). The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Cancer Treatment and Pharmacology & interferon and immune responses. The author has an h-index of 7, co-authored 14 publications.
ORCID: 0000-0003-0981-8311Papers by this author
worksUnresectable biliary tract cancer: Current and future systemic therapy
2024 · European Journal of Cancer · 19 citations
https://doi.org/10.1016/j.ejca.2024.114046
Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial
2022 · ESMO Open · 17 citations
https://doi.org/10.1016/j.esmoop.2022.100391
Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial
2024 · BMC Cancer · 2 citations
https://doi.org/10.1186/s12885-024-12599-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat